OTCMKTS:MEDXF Medexus Pharmaceuticals (MEDXF) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free MEDXF Stock Alerts $1.22 -0.02 (-1.61%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.22▼$1.2350-Day Range$1.11▼$2.0052-Week Range$0.84▼$2.56Volume8,031 shsAverage Volume18,840 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$17.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Medexus Pharmaceuticals alerts: Email Address Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About Medexus Pharmaceuticals Stock (OTCMKTS:MEDXF)Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.Read More MEDXF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDXF Stock News HeadlinesFebruary 12, 2024 | finance.yahoo.comMedexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Slashed Next Year's EstimatesFebruary 9, 2024 | wsj.comMedexus Pharmaceuticals Inc.March 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 9, 2024 | realmoney.thestreet.comMedexus Pharmaceuticals just downgraded at Raymond James, here's whyFebruary 7, 2024 | finance.yahoo.comMedexus Announces Fiscal Q3 2024 ResultsJanuary 8, 2024 | finance.yahoo.comHealth Canada Accepts for Review Medexus's New Drug Submission for Topical TerbinafineNovember 18, 2023 | seekingalpha.comMEDXF Medexus Pharmaceuticals Inc.November 8, 2023 | msn.comMedexus Pharmaceuticals reports Q2 resultsMarch 29, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…October 16, 2023 | finance.yahoo.comMedexus Fully Repays Convertible Debentures In Cash At MaturitySeptember 28, 2023 | finance.yahoo.comMedexus and medac Agree to Amend US Treosulfan AgreementSeptember 21, 2023 | finance.yahoo.comMedexus Holds Annual Meeting of Shareholders and Announces Election of DirectorsSeptember 5, 2023 | finance.yahoo.comMedexus Pharmaceuticals Announces C$10 Million Bought-Deal Public Offering of UnitsSeptember 5, 2023 | markets.businessinsider.comMedexus Pharmaceuticals Inc (MDP) Receives a Buy from Stifel NicolausSeptember 5, 2023 | finance.yahoo.comMedexus Strengthens Balance Sheet with US$18 Million Commitment Under Accordion FacilityAugust 17, 2023 | finance.yahoo.comMedexus Study Supports Efficacy and Safety of IXINITY in Pediatric Patients with Severe or Moderately Severe Hemophilia BAugust 9, 2023 | finance.yahoo.comMedexus Announces Strong Fiscal Q1 2024 Results, Including Record Quarterly Revenue of US$31.6 MillionAugust 2, 2023 | msn.comMedexus Pharmaceuticals (MEDXF) Price Target Increased by 8.32% to 2.73August 2, 2023 | finance.yahoo.comMedexus Schedules First Fiscal Quarter 2024 Conference CallJuly 12, 2023 | finance.yahoo.comMedexus Announces Preliminary Revenue for Fiscal Q1 2024June 15, 2023 | finance.yahoo.comFDA Accepts for Review Medexus's IXINITY Supplemental Biological License Application for Pediatric PatientsJune 14, 2023 | finance.yahoo.comMedexus Schedules Fourth Fiscal Quarter and Fiscal Year 2023 Conference CallJune 1, 2023 | finance.yahoo.comMedexus to Participate in the LD Micro Invitational XIIIMay 10, 2023 | finanznachrichten.deMedexus Pharmaceuticals Inc.: Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Convertible DebenturesMay 10, 2023 | finance.yahoo.comMedexus Announces Normal Course Issuer Bid, or NCIB, for Its Convertible DebenturesApril 11, 2023 | finance.yahoo.comMedexus Expects Record Revenue for Fiscal Year 2023 and Provides Business UpdateMarch 22, 2023 | finance.yahoo.comMedexus Announces New License Deal for Topical TerbinafineSee More Headlines Receive MEDXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:MEDXF CUSIPN/A CIKN/A Webwww.medexus.com Phone(514) 344-8765FaxN/AEmployees98Year FoundedN/APrice Target and Rating Average Stock Price Target$17.50 High Stock Price Target$17.50 Low Stock Price Target$17.50 Potential Upside/Downside+1,335.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Kenneth d'EntremontCEO & DirectorMr. Marcel Konrad (Age 48)Chief Financial Officer Comp: $585.05kMr. Ian C. Wildgoose BrownGeneral Counsel & Corporate SecretaryMs. Tina Byers CFAExecutive of Investor RelationsMr. Bill PoncySenior Vice President of Commercial Operations - United StatesMr. Brian PetersVice President of Sales & Marketing - United StatesMore ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors MEDXF Stock Analysis - Frequently Asked Questions Should I buy or sell Medexus Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MEDXF shares. View MEDXF analyst ratings or view top-rated stocks. What is Medexus Pharmaceuticals' stock price target for 2024? 1 Wall Street analysts have issued 12 month target prices for Medexus Pharmaceuticals' stock. Their MEDXF share price targets range from $17.50 to $17.50. On average, they anticipate the company's share price to reach $17.50 in the next year. This suggests a possible upside of 1,335.6% from the stock's current price. View analysts price targets for MEDXF or view top-rated stocks among Wall Street analysts. How have MEDXF shares performed in 2024? Medexus Pharmaceuticals' stock was trading at $1.89 at the start of the year. Since then, MEDXF stock has decreased by 35.5% and is now trading at $1.2190. View the best growth stocks for 2024 here. Are investors shorting Medexus Pharmaceuticals? Medexus Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 69,300 shares, an increase of 56.8% from the February 29th total of 44,200 shares. Based on an average daily trading volume, of 24,800 shares, the days-to-cover ratio is presently 2.8 days. View Medexus Pharmaceuticals' Short Interest. How do I buy shares of Medexus Pharmaceuticals? Shares of MEDXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MEDXF) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.